MAP3K8 and multiple sclerosis: Preclinical studies using genetic manipulation of TPL2 in mice have found that TPL2 deficiency provides beneficial effects in multiple inflammatory disease models, such as inflammatory bowel disease, psoriasis, pancreatitis, and multiple sclerosis (Senger et al., 2017; Sriskantharajah et al., 2014; Xiao et al., 2014; Xu et al., 2018), and TPL2 is being pursued as a target for treating inflammatory conditions including RA and psoriasis (Zarrin et al., 2021).